Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing therapy for inflammatory bowel diseases.

Expert review of gastroenterology & hepatology - 1 Aug 2013

Ananthakrishnan Ashwin N

Abstract excerpt

Inflammatory bowel diseases (IBDs; e.g., Crohn's disease [CD] and ulcerative colitis [UC]) are chronic immunologically mediated diseases characterized by frequent relapses, often requiring hospitalization and surgery. There is substantial heterogeneity in the progressive natural history of disease with cumulative accrual of bowel damage and impairment of functioning. Recent advances in therapeutics have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anti-Inflammatory Agents
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Gastrointestinal Agents

Share to Patient Selection

Share to Precision Medicine

Share to Treatment Outcome

Source

Identifiers

PMID: 23985004
DOI: 10.1586/17474124.2013.824693

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing therapy for inflammatory bowel diseases.PMID 23985004Read ↗

Personalizing therapy selection in inflammatory bowel disease.Semantic proximity Read ↗

Evolving Treatment Algorithms in Crohn's Disease.Semantic proximity Read ↗

Recent advances: Personalised use of current Crohn's disease therapeutic options.Semantic proximity Read ↗

The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity Read ↗

Future therapies for inflammatory bowel disease.Semantic proximity Read ↗

Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity Read ↗

Optimization and individualization of thiopurine therapy in inflammatory bowel disease: the great variability among drug responses.Semantic proximity Read ↗

New therapeutic strategies for treatment of inflammatory bowel diseaseSemantic proximity Read ↗

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsSemantic proximity Read ↗

Anticipating the onset of inflammatory bowel disease.Semantic proximity Read ↗

Treatment of inflammatory bowel disease from the immunological perspective.Semantic proximity Read ↗

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.